Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2011 Feb 2;10(4):670–678. doi: 10.1158/1535-7163.MCT-10-0781

Table.

Validated candidates in secondary screen

Gene Ratio of EUFA423/EUFA423B2 cell viability Gene
(Ave.± S.D.)
WEE1 0.10±0.02***
PLK1 0.10±0.14***
RAPGEF3 0.19±0.02
CDC27 0.19±0.04
COASY 0.22±0.07
MMC 0.29±0.04*
DUSP7 0.32±0.05
TSSK3 0.35±0.13
CHEK1 0.35±0.05***
EEF2K 0.36±0.05
CENPE 0.37±0.04***
PARP2 0.38±0.05*
FGFR4 0.38±0.02***
NTpool-1 1.18±0.08**
NTpool-2 1.17±0.05**
*

Positive control,

**

Negative control (non-target siRNA)

***

Validated by 2 siRNAs